SELECT * FROM `stock_list` WHERE `symbol` = "TRSBF" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='TRSBF' AND exchange = 'OTCPK' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "TRSBF" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 3SBio (TRSBF) Price-to-Funds-From-Operations
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Price-to-Funds-From-Operations

3SBio (TRSBF) Price-to-Funds-From-Operations : (As of May. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


3SBio (TRSBF) Business Description

Industry
Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.